Femasys Inc revenue
Femasys Inc's revenue was $2.3m in fiscal 2025, up 40.8% on the year before. Since fiscal 2020 ($1.0m) it has grown at a compound 17.2% a year. Over the last twelve months it was $2.3m.
Revenue history
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,038 | 1,180 | 1,206 | 1,072 | 1,629 | 2,293 | 2,299 |
| Growth on the year before | — | +13.7% | +2.2% | −11.1% | +52.0% | +40.8% | — |
| Gross profit | 731 | 809 | 764 | 692 | 1,084 | 1,421 | 1,401 |
| Gross margin | 70.5% | 68.6% | 63.4% | 64.5% | 66.6% | 62.0% | 60.9% |
Where the revenue comes from
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $1.4M | 60.8% | ▲ 29.8% |
| Outside the US | $899,758 | 39.2% | ▲ 61.9% |
From Femasys Inc's 10-K filed March 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Femasys Inc | $2.3m | 21.9% | 24.3% |
| Volitionrx LTD | $2.5m | 86.3% | 68.0% |
| Seastar Medical Holding Corp | $1.7m | 123.6% | — |
| Insight Molecular Diagnostics Inc. | $1.7m | -60.8% | 14.9% |
| Icecure Medical Ltd. | $3.4m | 2.7% | — |
| Cerenome, Inc. | $4.2m | -21.0% | 16.1% |
Compare with peers
- Volitionrx LTD revenue
- Seastar Medical Holding Corp revenue
- Insight Molecular Diagnostics Inc. revenue
- Icecure Medical Ltd. revenue
- Cerenome, Inc. revenue
Head to head: FEMY vs VNRXFEMY vs ICUFEMY vs IMDX
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies